ALAN MARCHBANKS: Open Payments
NPI 1992745103 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$624 in 36 payments from 13 companies in 2025. Trend: 2023 $919 · 2024 $658 · 2025 $624
Food & beverage: $624
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 15 | $150 |
| Sumitomo Pharma America, Inc. | 4 | $114 |
| Aimmune Therapeutics, Inc. | 4 | $92 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $76 |
| Gilead Sciences, Inc. | 1 | $30 |
| Corcept Therapeutics | 1 | $26 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
| ABIOMED | 1 | $19 |
Products named: GEMTESA, OTEZLA, ZENPEP, Kerendia, REPATHA, JARDIANCE, Korlym, SPRAVATO.
Industry payments across AZ — which companies pay providers there.
